Mr. Peter Bakema reports

CVR MEDICAL ENTERS CHINA, EXECUTES PRELIMINARY LOI TO LAUNCH ITS CSS DEVICE IN WORLD'S LARGEST MARKET

CVR Medical Corp. has signed an official letter of intent with Guangzhou LangRun Equity Investment Management Co., Ltd., a professional equity investment fund management platform company headquartered in Guangzhou, China. LangRun plans to create the LangRun Asset Fund, focused on investment in medical devices specific to senior care and health care optimization, and which will fund a proposed 35 per cent (CVR)/65 per cent (LangRun) joint venture to market, assemble and distribute CVR's patented carotid stenotic scan (CSS) device throughout mainland China.

The letter of intent puts CVR in a position to achieve its goal of further expansion into the Asia-Pacific market upon the intended launch of the CSS in 2018. By working in unison with LangRun, CVR will enter the Chinese market with the financial resources, stability and guidance necessary to build necessary infrastructure, grow brand awareness and reach a population of nearly 1.5 billion. LangRun's breadth of business experience in the region, combined with the commitment to finance the project in its entirety, will ensure that all operational and clinical requirements are substantiated and every effort is made to achieve approval by the Chinese Food and Drug Administration for market entry.

"We are excited about this proposed equity JV with Guangzhou LangRun to develop the mainland Chinese market for our CSS medical device, which will leverage the strength of LangRun's strategic partners in government, political, financial and health care circles. The agreement we have in place with Guangzhou LangRun will pave the way to one of CVR's primary goals, entrance into the Chinese market through an equity-based joint venture," stated CVR chief executive officer, Peter Bakema. "CVR sees this as a turnkey moment in our evolution into a globally recognized company within the medical-device industry. It is a point of great pride for us, and we look forward to working with LangRun and its partners to bring our technology to the people of China. This joint venture will act as the framework of future global opportunities for CVR's patented CSS device. With a significant investment of tens of millions of dollars dedicated to the funding of operational infrastructure, which includes manufacturing, marketing, and sales, CVR is effectively able to work with LangRun and bring this project to profitability. In addition, the joint venture also calls for the payment of advance royalties, and altogether is expected to be dwarfed by the ROI (return on investment) generated by the joint venture. CVR is currently negotiating several similar opportunities globally."

LangRun and CVR are working diligently to define the final terms of the joint-venture agreement.

For additional information on the organization, leadership and current news please visit CVR's newly launched company website.

About CVR Medical Corp.

CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. The joint venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.

We seek Safe Harbor.